Literature DB >> 1366870

Effects of mutations altering SOS regulation on a nalidixic acid-inducible system for the production of heterologous proteins in Escherichia coli.

J Keller1, R Gerber, B J Del Tito, D Vannicolo, E J Arcuri.   

Abstract

The major leftward early promoter of phage lambda pL, has frequently been used to drive expression of heterologous genes in Escherichia coli. pL is typically maintained fully repressed by the lambda cl protein. When induction of heterologous protein synthesis is desired, one of several potential mechanisms of destroying cl function is employed and the expression of the foreign gene commences. One method of derepressing pL involves exposing cells to nalidixic acid, which results in the "activation" of RecA protein and the subsequent RecA-mediated proteolytic cleavage of cl. Activated RecA also mediates the cleavage of the E. coli LexA protein, resulting in induction of the SOS regulon (at least 15 E. coli genes, including recA). We have examined the effect of two chromosomal mutations on the productivity of nalidixic acid inductions. One of the tested mutations (recA o) increased the intracellular concentration of RecA prior to induction; the other (lexAind-) resulted in a mutated lexA protein insensitive to RecA-mediated cleavage. These mutations were introduced into a strain carrying a cl+ defective lysogen. Synthesis of two heterologous proteins, human alpha 1-antitrypsin and a fusion protein partially derived from the Plasmodium falciparum circumsporozoite surface antigen, was examined in the wild-type and mutant strains. The maximum alpha-1 antitrypsin concentration achieved was improved by 50% when the recA o strain was used rather than the wild-type; however, only smaller changes (20% or less) in the maximum concentration of the malaria fusion protein were observed. Use of the lexAind- strain resulted in a decrease in the maximum concentration attained for both heterologous products.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1366870     DOI: 10.1007/bf01577696

Source DB:  PubMed          Journal:  J Ind Microbiol        ISSN: 0169-4146


  37 in total

1.  High-level production of fully active human alpha 1-antitrypsin in Escherichia coli.

Authors:  H Johansen; J Sutiphong; G Sathe; P Jacobs; A Cravador; A Bollen; M Rosenberg; A Shatzman
Journal:  Mol Biol Med       Date:  1987-10

2.  Expression, identification, and characterization of recombinant gene products in Escherichia coli.

Authors:  A R Shatzman; M Rosenberg
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

3.  Detection of alpha 1-antitrypsin from recombinant Escherichia coli lysates utilizing the particle concentration fluorescence immunoassay.

Authors:  B J Del Tito; D W Zabriskie; E J Arcuri
Journal:  J Immunol Methods       Date:  1988-02-24       Impact factor: 2.303

Review 4.  Ultraviolet mutagenesis and inducible DNA repair in Escherichia coli.

Authors:  E M Witkin
Journal:  Bacteriol Rev       Date:  1976-12

5.  The use of pKc30 and its derivatives for controlled expression of genes.

Authors:  M Rosenberg; Y S Ho; A Shatzman
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

6.  Regulation of the genes for E. coli DNA gyrase: homeostatic control of DNA supercoiling.

Authors:  R Menzel; M Gellert
Journal:  Cell       Date:  1983-08       Impact factor: 41.582

Review 7.  The SOS regulatory system of Escherichia coli.

Authors:  J W Little; D W Mount
Journal:  Cell       Date:  1982-05       Impact factor: 41.582

8.  Modulation of gene expression by drugs affecting deoxyribonucleic acid gyrase.

Authors:  B Sanzey
Journal:  J Bacteriol       Date:  1979-04       Impact factor: 3.490

9.  Antielastases of the human alveolar structures. Implications for the protease-antiprotease theory of emphysema.

Authors:  J E Gadek; G A Fells; R L Zimmerman; S I Rennard; R G Crystal
Journal:  J Clin Invest       Date:  1981-10       Impact factor: 14.808

10.  Nalidixic Acid and the Metabolism of Escherichia coli.

Authors:  E B Winshell; H S Rosenkranz
Journal:  J Bacteriol       Date:  1970-12       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.